Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over-the-counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, announced that it expects to implement a 1-for-20 reverse stock split, or consolidation of its issued and unissued Class A ordinary shares and Class B ordinary shares, par value $0.001 per share (the "Ordinary Shares"), effective at the opening of market of October 26, 2026 (the "Reverse Stock Split"). Trading in the Class A Ordinary Shares on a split-adjusted basis will continue on Nasdaq on October 26, 2026 under the symbol "HKPD." The new CUSIP number for the Company’s Ordinary Shares post-Reverse Stock Split is G6365B112.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.